Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Other current assets consisted of the following as of March 31, 2021 and December 31, 2020:

	March 31, 2021		December 31, 2020
	(unaudited)
Lab supply inventory	$	2,227	$	2,052
Prepaid expenses		560		625
Other		188		45
Total other current assets	$	2,975	$	2,722

Schedule of Basic and Diluted Net Loss Per Share

A reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2021 and 2020 is as follows:

	Three Months Ended
	March 31,
	2021		2020
	(unaudited)
Basic weighted average number of common shares		4,089		4,004
Potential dilutive effect of stock-based awards		-		-
Diluted weighted average number of common shares		4,089		4,004

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares for the three- months ended March 31, 2021, and the following outstanding stock-based awards and warrants, were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

	Three Months Ended
	March 31,
	2021		2020
	(unaudited)
Options		1,061		578
Restricted stock and restricted stock units (RSUs)		395		42
Warrants		1,405		1,420
		2,861		2,040